ERBB2 and breast carcinoma: Plant-derived vaccines, for instance, have been engineered to express antigens such as HER2, a protein overexpressed in breast cancer, or mucin-1, a glycoprotein frequently expressed in ovarian and breast cancer; such vaccines have shown potential in preclinical studies as immunotherapeutic agents for cancer treatment [147,148].